DOP69: Longitudinal gut microbiome dynamics in relation to disease flares in Inflammatory Bowel Disease, pilot data from the IBD-Tracker studyECCO'24 Stockholm
2024
DOP70: Prevalence and severity of bowel urgency in Crohn’s Disease: Results from the Communicating Needs and Features of IBD Experience (CONFIDE) SurveyECCO'24 Stockholm
2024
DOP71: Efficacy of once-daily, orally administered obefazimod in patients with moderately to severely active UC at weeks 8, 48, and 96 broken down by induction treatment doseECCO'24 Stockholm
2024
DOP72: Pregnancy for IBD-patients with an enterostomy is feasible but is associated with complicationsECCO'24 Stockholm
2024
DOP73: Early biological use in a Belgian, prospective inception cohort of patients with Inflammatory Bowel Disease: the PANTHER cohortECCO'24 Stockholm
2024
DOP74: Short and long-term effectiveness and safety of ustekinumab in Ulcerative Colitis in real life: the ULISES studyECCO'24 Stockholm
2024
DOP75: Frequency and effectiveness of dose escalation of biologic therapy in Inflammatory Bowel Disease: The RAINBOW-IBD study of ENEIDAECCO'24 Stockholm
2024
DOP77: Mesenchymal stem cell therapy for refractory Crohn’s perianal fistulas: a case seriesECCO'24 Stockholm
2024
DOP78: Efficacy of ozanimod by patient response trajectory subgroups identified using group-based trajectory modelling: a post hoc analysis of the phase 3 True North studyECCO'24 Stockholm
2024
DOP79: Promising efficacy of biologicals and small molecules for microscopic colitis: results from a large real-life multicenter cohortECCO'24 Stockholm
2024
DOP80: Prevalence and factors associated with Inflammatory Bowel Disease (IBD) activity during pregnancy: updated data from the DUMBO RegistryECCO'24 Stockholm
2024
DOP84: Colonic CD4+ T cell senescence is implicated in the progression of experimental colitis in aged miceECCO'24 Stockholm
2024
DOP85: An anti-fibrotic role for eosinophils in a DSS colitis RAG-/- and an in vitro co-culture modelECCO'24 Stockholm
2024
DOP86: FOod Additives on the Mucosal barrier study (FOAM): Effect of five emulsifiers on inflammation, intestinal permeability, and the microbiome: preliminary results.ECCO'24 Stockholm
2024